Lingfeng Chen

182 Tianmushan Rd
Hangzhou, 310013, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Gallium-68 Labeled Cyclic Glycopeptides for Liver Function Imaging.

Gallium-68 Labeled Cyclic Glycopeptides for Liver Function Imaging.

Journal: Journal of medicinal chemistry

Published: April 10, 2026

Converting FGFR inhibitors into selective covalent molecular glue degraders via transposable gluing handles.

Converting FGFR inhibitors into selective covalent molecular glue degraders via transposable gluing handles.

Journal: European journal of medicinal chemistry

Published: March 31, 2026

Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.

Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.

Journal: Nature communications

Published: December 24, 2025

Next-generation isoform-selective fibroblast growth factor receptor inhibitors.

Next-generation isoform-selective fibroblast growth factor receptor inhibitors.

Journal: Trends in pharmacological sciences

Published: August 14, 2025

Microneedle-delivered ROS-adaptive asiatic acid nanoparticles promote scarless repair via remodeling the pathological microenvironment.

Microneedle-delivered ROS-adaptive asiatic acid nanoparticles promote scarless repair via remodeling the pathological microenvironment.

Journal: Journal of nanobiotechnology

Published: July 23, 2025

LC-MF-4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3-Altered Cancers.

LC-MF-4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3-Altered Cancers.

Journal: Journal of medicinal chemistry

Published: June 27, 2025

Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer.

Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer.

Journal: European journal of medicinal chemistry

Published: April 02, 2025

Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer.

Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer.

Journal: Journal of pharmaceutical analysis

Published: December 21, 2024

Discovery of Novel MyD88 Inhibitor A5S to Alleviate Acute Lung Injury with Favorable Drug-like Properties.

Discovery of Novel MyD88 Inhibitor A5S to Alleviate Acute Lung Injury with Favorable Drug-like Properties.

Journal: Journal of medicinal chemistry

Published: December 07, 2024

Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.

Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.

Journal: Journal of medicinal chemistry

Published: May 09, 2024

Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injury.

Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injury.

Journal: Bioorganic chemistry

Published: December 24, 2023

Synergistic anti-oxidant and anti-inflammatory effects of ceria/resatorvid co-decorated nanoparticles for acute lung injury therapy.

Synergistic anti-oxidant and anti-inflammatory effects of ceria/resatorvid co-decorated nanoparticles for acute lung injury therapy.

Journal: Journal of nanobiotechnology

Published: September 25, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026